Skip to Main Content

Paper Details

Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease.
Gut
11
2022
Author NameAffiliation
Rishi J DesaiDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School
Sebastian SchneeweissDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School
  • 1 - 2

Datasets

Release 1.2